US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their […]
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s mega-blockbuster down precipitously. But the […]
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis (PsA) launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake. […]
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global Insights EXTON, PA, February 13, 2025 – UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a […]
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights
Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy regimen until an initial failure. EXTON, PA., January 9, 2025 – At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management of Lupus Nephritis (LN)—the […]
Uptake of Benlysta, Saphnelo signal ‘exciting time’ for ‘lupologists’
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights. A top-line data point from the survey suggests that, among patients with SLE currently treated with biologics by the 100 rheumatologist respondents, 62% were receiving belimumab (Benlysta, GlaxoSmithKline) as of […]
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities, including the reduction […]
‘The most challenging disease’: Misdiagnoses, unmet needs abound in systemic sclerosis
Systemic sclerosis is the most challenging diagnosis to make among rheumatic and autoimmune conditions, according to 91% of respondents in a market analysis from Spherix Global Insights. “I agree with the survey responses in that the rheumatologists highlighted systemic sclerosis as the most challenging diagnosis and the most challenging disease to manage in practice,” Dinesh Khanna, MD, MSc, professor […]
Survey: U.S. Derms and Rheums Report “Extremely High” Unmet Need for New Treatments in DM
More than half of dermatomyositis patients are not optimally managed, according to a survey of 102 U.S. rheumatologists and dermatologists by Spherix Global Insights. Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or off-label biologics, underscoring the growing […]
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics’brepocitinib. Exton, PA, October 18, 2024 – Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care predominantly involves corticosteroids, topical therapies, […]
